Alnylam Pharmaceuticals ALNY hit a new 52-week high on Monday after it reported positive top-line results from a late-stage study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic,...
Source LinkAlnylam Pharmaceuticals ALNY hit a new 52-week high on Monday after it reported positive top-line results from a late-stage study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic,...
Source Link
Comments